Bridging-Therapy

• Deep-Dive: MR CLEAN M2 Registry — Bridging Therapy Edges Out Direct EVT for M2 Occlusions

  August 15, 2026

  MR CLEAN Registry M2 analysis (n=539): bridging IV thrombolysis before EVT improves 90-day mRS vs direct EVT (aOR 1.52, P=0.03); sICH and recanalization similar.

• Deep-Dive: T-FLAVOR — Tenecteplase 0.25 mg/kg vs Low-Dose Alteplase in LVO Stroke

  August 11, 2026

  T-FLAVOR Japanese phase 2 (n=218): tenecteplase vs low-dose alteplase for LVO bridging — substantial reperfusion 10.3% vs 3.6% (90% CI 0.89–12.1; 95% CI −0.19% to 13.2%; mRS shift favors TNK numerically).